Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Omnicell reports robust Q4 earnings, eyes Advanced Services growth

Omnicell's Q4 2022 earnings call highlighted a strong financial performance, cost-saving initiatives, and strategic priorities for 2023. The company aims to drive growth through Advanced Services expansion, while navigating challenges such as market conditions and regulatory impacts. By focusing on operational efficiency and prudent financial management, Omnicell positions itself for sustainable growth and profitability.

Omnicell surpasses Q1 revenue targets, eyes automation for growth

Omnicell's Q1 2023 earnings call showcased robust financial performance, strategic partnerships, and cost containment efforts. The company is well-positioned to capitalize on the growing demand for automation in healthcare.

Omnicell surpasses Q2 expectations, focuses on AI strategy growth

Omnicell's Q2 performance exceeded expectations, driven by strong revenues and margins.
The company's strategic strengths lie in customer wins, AI focus, and margin management.
Challenges include market dynamics and the need for ongoing adjustments.
Opportunities for growth include raised guidance, AI strategy development, and CMS impact.

Omnicell reports Q3 earnings, faces challenges but eyes growth opportunities

Omnicell's Q3 2023 performance reflects solid total revenues, EBITDA, and EPS, with market challenges impacting bookings and product lines. The company's strengths include customer wins, profitability, and strategic growth initiatives.
Challenges include revenue impact from reduced bookings, point-of-care revenue decline, and pipeline deal deferrals. Opportunities exist in Advanced Services growth, market expansion, and cost management strategies.
Omnicell's focus on profitability, revenue growth, and customer value delivery positions it for future success. The company's strategic actions and financial outlook indicate a proactive approach to addressing challenges and seizing opportunities.

Omnicell reports Q4 revenue decline but sees growth opportunities ahead

Omnicell's Q4 2023 performance saw revenue decline but highlighted strategic wins and a focus on operational optimization.
The company's strengths lie in customer engagement, product upgrades, and expansion into new markets.
Challenges include industry costs and regulatory hurdles, but opportunities exist in market growth and service enhancements.
Overall, Omnicell remains optimistic about future demand and revenue potential, with a conservative outlook for Q1.

Omnicell surpasses Q1 revenue targets, exits product line for value

Omnicell's Q1 2024 earnings call showcased strong performance exceeding guidance, with a focus on cost management and strategic initiatives. The company announced plans to exit an international product line to improve shareholder value. Opportunities lie in the growth of the XT Amplify program and EnlivenHealth brand, despite challenges in revenue decline and operational decisions.

Omnicell reports robust Q3 earnings, eyes growth in healthcare solutions

Omnicell's Q3 2024 performance reflects strong revenue growth and operational resilience in healthcare solutions.
The company's strategic focus on customer-centricity and innovation positions it for sustained success.
Challenges in product revenue timing and cost optimization require ongoing attention for operational efficiency.
Opportunities in expanding services and market positioning offer avenues for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Fort Worth, TX.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Spartanburg Regional Healthcare System Partners with Omnicell to Drive Improved Clinical and Operational Outcomes

Spartanburg Regional Healthcare System Partners with Omnicell to Drive Improved Clinical and Operational Outcomes

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced results for its second quarter ended June 30, 2021. GAAP Results Total revenues for the second quarter of 2021 were $272.7 million, up $73.1 million, or 36.6%, from the second quarter of 2020. The increase in revenues reflects momentum in our commercial business and strong customer implementations a

Omnicell Announces Financial Results for Second Quarter 2021

Omnicell's (OMCL) second-quarter 2021 guidance includes additional freight costs, given the ongoing global market conditions.

Omnicell (OMCL) Faces Lingering Cost Woes, Fierce Competition

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Acquire FDS Amplicare

Omnicell to Acquire FDS Amplicare

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Appoints Edward Bousa to Board of Directors

Omnicell Appoints Edward Bousa to Board of Directors

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Second Quarter 2021 Financial Results on July 29, 2021

Omnicell to Release Second Quarter 2021 Financial Results on July 29, 2021

Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.

Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow

PITTSBURGH--(BUSINESS WIRE)--Chartwell Enhances IV Preparations with Omnicell® IVX Workflow

Chartwell Enhances IV Preparations with Omnicell® IVX Workflow

Within the last quarter, Omnicell (NASDAQ:OMCL) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1 0 Somewhat Bullish 1 0 1 0 Indifferent 0 1 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for Omnicell. The company has an average price target of $162.2 with a high of $188.00 and a low of $146.00.

Where Omnicell Stands With Analysts

Lordstown Motors

ResMed

Checkpoint Therapeutics

Helix Energy Solutions Group

Home Point Capital

Morgan Stanley

Renewable Energy Group

Weatherford International PLC

With the trading day about halfway over, the markets were trading sideways yet again, and it seems like the major averages may be stuck on this plateau.

Lordstown, Morgan Stanley, ResMed and More Wednesday Afternoon Analyst Calls

Omnicell, Inc. (OMCL) CEO Randall Lipps on Q1 2021 Results - Earnings Call Transcript

Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.

Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand

Omnicell (OMCL) delivered earnings and revenue surprises of 23.88% and 2.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Omnicell (OMCL) Surpasses Q1 Earnings and Revenue Estimates

Shares of Omnicell (NASDAQ:OMCL) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 25.76% over the past year to $0.83, which beat the estimate of $0.66.

Omnicell: Q1 Earnings Insights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, today announced that Scripps Health has selected the Company's industry-leading medication management platform to improve pharmacy supply chain management across its San Diego-based network. Scripps Health has signed a multi-year sole source agreement for Omnicell solutions. Through this new partnership, Omnicell will

Scripps Health Selects Omnicell Medication Management Solutions to Help Improve Clinical and Operational Efficiency

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Financial Results for First Quarter 2021

Omnicell Announces Financial Results for First Quarter 2021

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--EnlivenHealth Partners with Twilio to Accelerate Launch of Transformative Patient Communications Solutions

EnlivenHealth Partners With Twilio to Accelerate Launch of Transformative Patient Communications Solutions

Putting progress ahead of politics is just one lesson Omnicell CEO Lipps picked up while building the leader in a key corner of the health care business. The post Why Omnicell's CEO Puts Progress Over Politics appeared first on Investor's Business Daily.

Why Omnicell's CEO Puts Progress Over Politics

Investors are optimistic about Omnicell (OMCL) owing to its progress with its three-legged strategic, which is driving growth and an impressive 2025 roadmap.

Here's Why You Should Hold on to Omnicell (OMCL) Stock Now

Omnicell's (OMCL) Autonomous Pharmacy vision receives another boost with the latest service adoption by Aultman.

Omnicell's (OMCL) Automated Dispensing Service Adopted by Aultman

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aultman Health Foundation to Enhance Medication Management with Omnicell's Central Pharmacy Dispensing Service

Aultman Health Foundation to Enhance Medication Management with Omnicell's Central Pharmacy Dispensing Service

Omnicell (OMCL) expands its autonomous pharmacy portfolio with the acquisition of PSG's 340B Link business.

Omnicell's (OMCL) 2025 Roadmap Impressive, Pandemic Woe Stays

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release First Quarter 2021 Financial Results on April 29, 2021

Omnicell to Release First Quarter 2021 Financial Results on April 29, 2021

Omnicell (OMCL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Omnicell (OMCL) Moves 4.9% Higher: Will This Strength Last?

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?

News for Omnicell Stock (OMCL)